# UAB Ligence

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/uab-ligence

- Industry: Healthcare IT
- Headquarters: Vilnius, Lithuania
- Website: www.ligence.io
- Total disclosed funding: $3.3M
- Latest round: Seed (Oct 12, 2024)
- Investors on record: 5

## About

UAB Ligence, founded in 2019 in Lithuania, focuses on echocardiography solutions. The company raised EUR 3 million in a Seed round on November 12, 2024, led by Simpact Fund with participation from various investors. Arnas Karuzas is leading the firm as CEO as of 2024.

Ligence offers echocardiography analysis and reporting software, particularly through its flagship product, Ligence Heart™. This web-based platform leverages deep learning technologies to support echocardiographic assessments. Key functionalities include automated image analysis for right and left ventricular evaluation, prediction of diastolic dysfunction, and a streamlined workflow that allows cardiologists to focus on patient interaction rather than multitasking during examinations. The software is designed for healthcare professionals within cardiology, particularly serving hospitals and clinics that require precise cardiac imaging and reporting. Ligence Heart is marketed primarily in Europe, North America, and select regions in Asia, targeting hospitals and specialized cardiovascular practices that utilize echocardiography in their diagnostic processes. 

The revenue structure of Ligence is built upon a subscription-based model for its Ligence Heart™ software, catering to healthcare institutions and professionals. Clients engage in annual or monthly subscription agreements, where they gain access to the platform’s suite of tools for echocardiography analysis. Additionally, Ligence may establish partnerships with hospitals and medical facilities for tailored integrations with existing PACS (Picture Archiving and Communication Systems) and EHR (Electronic Health Record) systems. Specific pricing plans for the subscription services are set to reflect the software's advanced capabilities and the scale of deployment across institutions, emphasizing its role in improving diagnostic workflows within the healthcare sector. 

In November 2024, UAB Ligence raised EUR 3 million in Seed funding led by Simpact Fund, with participation from Coinvest Capital, European Innovation Council and SMEs Executive Agency, Lemonade Stand, and NGL Ventures. This funding will be utilized to support the company's expansion efforts. Plans are in place to design and launch new features and enhancements for Ligence Heart™ in the coming year, with the intent to further penetrate the North American market by mid-2025.

## Funding rounds

- Seed, Oct 12, 2024, $3.3M — Coinvest Capital, European Innovation Council, Simpact Fund, Lemonade Stand, NGL Ventures

## Investors

- Coinvest Capital (https://capitalatlas.ai/funds/coinvest-capital) — Seed
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Seed
- Simpact Fund (https://capitalatlas.ai/funds/simpact-fund) — Seed
- Lemonade Stand (https://capitalatlas.ai/funds/lemonade-stand) — Seed
- NGL Ventures — Seed